Coherus BioSciences (CHRS) Announces Repurchase of Approximately $170M of Convertible Notes
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
Coherus Announces Repurchase of Approximately $170 Million of Convertible Notes
April 1, 2025 8:00 AM EDTRemaining $60 Million of outstanding convertible notes to be repurchased post-close of pending UDENYCA divestiture
REDWOOD CITY, Calif., April 01, 2025 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Coherus or the Company, NASDAQ: CHRS) announced today that it has entered into privately negotiated transactions (the Repurchases) with certain holders (the Holders) of its 1.500% Convertible Senior Subordinated Notes due 2026 (the Convertible Notes), pursuant to which the Company agreed to repurchase approximately $170 million aggregate principal amount of the Convertible Notes from such holders at a cash repurchase price equal to 100% of their principal amount,... More
